Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Tax Provisions (2019 - 2026)

Neurocrine Biosciences filings provide 7 years of Tax Provisions readings, the most recent being $85.7 million for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 44.03% to $85.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $226.8 million, a 56.74% increase, with the full-year FY2025 number at $226.8 million, up 56.74% from a year prior.
  • Tax Provisions hit $85.7 million in Q4 2025 for Neurocrine Biosciences, up from $82.3 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $85.7 million in Q4 2025 to a low of -$26.7 million in Q1 2023.
  • Median Tax Provisions over the past 5 years was $27.5 million (2022), compared with a mean of $26.3 million.
  • Biggest five-year swings in Tax Provisions: soared 1500.0% in 2021 and later crashed 456.0% in 2023.
  • Neurocrine Biosciences' Tax Provisions stood at -$6.5 million in 2021, then skyrocketed by 544.62% to $28.9 million in 2022, then surged by 74.74% to $50.5 million in 2023, then rose by 17.82% to $59.5 million in 2024, then soared by 44.03% to $85.7 million in 2025.
  • The last three reported values for Tax Provisions were $85.7 million (Q4 2025), $82.3 million (Q3 2025), and $52.0 million (Q2 2025) per Business Quant data.